Evidence map›Paper›PMID 24842524›Full record

Trial reportBone marrow transplantation2014

Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT.

A Xhaard, H Moins-Teisserenc, M Busson, M Robin, P Ribaud, N Dhedin, S Abbes, M Carmagnat, V-D Kheav, G Maki and 3 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Impact of CD34Blood research · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A XhaardService d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
H Moins-Teisserenc1] Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Inserm UMRS-940, Institut Universitaire d'Hématologie, Paris, France [3] Université Paris-Diderot et Paris Sorbonne Cité, Paris, France.
M BussonInserm UMRS-940, Institut Universitaire d'Hématologie, Paris, France.
M RobinService d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
P RibaudService d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
N DhedinService d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
S AbbesService d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
M CarmagnatLaboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
V-D Kheav1] Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Paris-Diderot et Paris Sorbonne Cité, Paris, France.
G MakiLaboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
R Peffault de LatourService d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
A Toubert1] Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Inserm UMRS-940, Institut Universitaire d'Hématologie, Paris, France [3] Université Paris-Diderot et Paris Sorbonne Cité, Paris, France.
G Socié1] Service d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Inserm UMRS-940, Institut Universitaire d'Hématologie, Paris, France [3] Université Paris-Diderot et Paris Sorbonne Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies on regulatory T-cell (Treg) reconstitution after allogeneic hematopoietic SCT (HSCT) have suggested that, within the GVHD process, imbalance between effector T cells and Tregs may be more important than the absolute numbers of circulating Tregs. No study has analyzed naive vs memory Treg reconstitution in a longitudinal cohort with large numbers of patients. The reconstitution of total and subsets of Treg was prospectively analyzed by flow cytometry in 185 consecutive recipients at 3, 6, 12 and 24 months after allogeneic HSCT. The levels of total, naive and memory Tregs increased, mainly within the memory subset, but remained lower than healthy controls up to 2 years after transplantation. Reduced-intensity conditioning and peripheral blood (PBSC) as the source of stem cells were associated with better 3-month reconstitution. In multivariate analysis, PBSC, recipient age ⩽25 and no anti-thymoglobulin in the conditioning regimen were associated with a better Treg reconstitution. Naive Treg long-term reconstitution was mainly influenced by recipient age. Whereas prior acute GVHD impaired Treg reconstitution, Treg subsets (absolute numbers and frequencies relative to CD4(+) T-cell subsets) at 3, 6 and 12 months after HSCT were not associated with the occurrence of a later episode of chronic GVHD.

Indexed as

Hematopoietic Stem Cell TransplantationImmunologic MemoryAdolescentAdultAgedAllograftsChildGraft vs Host DiseaseHematologic NeoplasmsHumansMaleMiddle AgedProspective StudiesRecovery of FunctionTime FactorsT-Lymphocytes, Regulatory

Identifiers

PMID24842524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.